Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevirimat Dose-Ranging Study in HIV-1
NCT00967187Phase 2Completed
- Sponsor
- Myrexis, Inc.
- Start
- May 2008
- Primary completion
- Nov 2009
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevirimat in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Myrexis, Inc. Primary endpoint: Change in HIV-1 viral load from baseline to day 15. Started May 2008; status: completed.
02
Drugs
bevirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00967187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967187.